AUIN

With the increase of resistant bacterias to the drugs used in the conventional treatment of tuberculosis, it is necessary to improve the activity of existing drugs or the development of new active drugs.

The developed compounds proved to be effective in vitro against the main causative agent of Tuberculosis, Mycobacterium tuberculosis, sensitive to the current therapeutic regimen, as well as to the mono and Multi-drug-resistant clinical isolates.

The compounds developed have a high inhibitory activity against M. tuberculosis, as efficient or superior to the topical drugs currently used for treatment (rifampicin, isoniazid, ethambutol and pyrazinamide), with minimal cytotoxic effects in in vitro, culture macrophage cells. The big difference is also to act on the bacteria resistant to the current drugs. The use of the compounds would bring numerous benefits, such as:

• Efficient treatment against tuberculosis and possible treatment against resistant tuberculosis;
• Treatment time reduction;
• With greater efficiency and less time, the new drug should reduce abandonment and treatment costs.